Vivendy Therapeutics gets 10.5m venture injection
BioMedInvest, Life Science Partners and TVM Capital have invested in a €10.5m first round of funding for Basel-based bio-pharmaceutical company Vivendy Therapeutics.
Vivendy is developing an enzyme replacement therapy (ERT) for Morbus Morquio (MPS IVA), a rare lysosomal storage disease.
Morbus Morquio...